Thermo Fisher Scientific reported earnings per share of $6.68 against an estimate of $6.40, and revenue of $12.14 billion against an estimate of $11.95 billion, a beat on both counts. Despite that, shares traded at $662.00 before the open, down 3.69% against the prior close of $687.37.
| Measure | Reported | Estimate | Result |
|---|---|---|---|
| Earnings per share | $6.68 | $6.40 | Beat |
| Revenue | $12.14 billion | $11.95 billion | Beat |
Source: Company earnings report and sell-side analyst consensus estimates · as of October 21, 2026 at 7:31 AM ET · Reported before the open on Wednesday, October 21, 2026.
Against the quarters before
Thermo Fisher has beaten estimates in each of the last four quarters on the table. In July 2026 it posted EPS of $6.03 against $5.72 expected on revenue of $11.99 billion; in April 2026, EPS of $5.44 against $5.25 expected on revenue of $11.01 billion; in January 2026, EPS of $6.57 against $6.45 expected on revenue of $12.21 billion; and in October 2025, EPS of $5.79 against $5.50 expected on revenue of $11.12 billion.
| Reported | EPS | Estimate | Revenue | EPS result |
|---|---|---|---|---|
| July 23, 2026 | $6.03 | $5.72 | $11.99 billion | Beat |
| April 23, 2026 | $5.44 | $5.25 | $11.01 billion | Beat |
| January 29, 2026 | $6.57 | $6.45 | $12.21 billion | Beat |
| October 22, 2025 | $5.79 | $5.50 | $11.12 billion | Beat |
Source: Company earnings reports and the consensus estimates at the time
How the stock took it
Shares fell premarket to $662.00, a drop of 3.69% from the prior close of $687.37, even after the company topped both estimates. No comments or guidance from company management are included in the facts provided. Traders on X were discussing the report as part of a busy morning of large-company releases, circulating preview figures on revenue and adjusted earnings and noting interest in topics such as life-sciences demand and research funding, though these were shared estimates rather than the company's own statements.
| Measure | Value |
|---|---|
| Last close | $687.37 |
| Price | $662.00 |
| Change | -3.69% |
Source: Extended-hours trades against the regular close · as of October 21, 2026 at 7:31 AM ET · Extended-hours trading is thin; the price can move a long way before the open.
Who it buys from and sells to
Company filings name Bio-Techne, Solventum, Idexx Laboratories and Bayer as customers of Thermo Fisher, and Sanofi, Federal Express, DHL and Solventa as suppliers. This mix of life-sciences customers and logistics suppliers reflects how Thermo Fisher's instruments, reagents and distribution network connect it to a wide span of the healthcare and research supply chain.
| Company | Role | Stock | Last move |
|---|---|---|---|
| Bio-Techne | Customer | TECH | +0.12% |
| Solventum | Customer | SOLV | +1.58% |
| Idexx Laboratories | Customer | IDXX | +0.38% |
| Sanofi | Supplier | SNY | +4.62% |
| Federal Express | Supplier | Not listed | — |
| DHL | Supplier | Not listed | — |
| Solventa | Supplier | Not listed | — |
| Bayer | Customer | Not listed | — |
Source: Relationships named in company filings (SEC 10-K annual report; Earnings call transcript); stock quotes · as of October 21, 2026 at 7:31 AM ET · Named in filings; a neighbour's move is not evidence of a link to this report.